The Cancer Genome Atlas (TCGA) has identified four groups of carcinomas: Group 1, with POLE mutations, is associated with a good prognosis; Group 2, with microsatellite instability, is associated with an intermediate prognosis; Group 3, showing low copy-number alterations, is also associated with an intermediate prognosis; and Group 4, with high copy-number alterations and TP53 mutations, is associated with a poor prognosis [2]. This evidence concerns the gene TP53 and carcinoma.